Quince Therapeutics, Inc. (QNCX)
2025-06-30 | ||||
|---|---|---|---|---|
| Unrealized gain (loss) on available-for-sale securities | -17 | |||
| Foreign currency translation adjustments | 4,216 | |||
| Income tax expense | 67 | |||
| Other income (expense), net | -29 | |||
| Research and development | 6,553 | |||
| Goodwill impairment charge | - | |||
| General and administrative | 3,342 | |||
| Fair value adjustment for contingent consideration | 532 | |||
| Total operating expenses | 10,427 | |||
| Loss from operations | -10,427 | |||
| Interest income | 311 | |||
| Warrant issuance costs | 872 | |||
| Fair value adjustment for warrants | 4,464 | |||
| Fair value adjustment for long-term debt | 501 | |||
| Net loss before income tax expense | -15,982 | |||
| Net loss | -16,049 | |||
| Total comprehensive loss | -11,850 | |||
| Earnings per share, basic | -0.34 | |||
| Earnings per share, diluted | -0.34 | |||
| Weighted average number of shares outstanding, basic | 46,686,239 | |||
| Weighted average number of shares outstanding, diluted | 46,686,239 | |||